• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk stratification in therapy-related myelodysplastic syndromes.

作者信息

Zeidan Amer M

机构信息

Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.

出版信息

Oncotarget. 2017 Sep 24;8(46):80103-80104. doi: 10.18632/oncotarget.21178. eCollection 2017 Oct 6.

DOI:10.18632/oncotarget.21178
PMID:29113285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5655180/
Abstract
摘要

相似文献

1
Risk stratification in therapy-related myelodysplastic syndromes.治疗相关骨髓增生异常综合征的风险分层
Oncotarget. 2017 Sep 24;8(46):80103-80104. doi: 10.18632/oncotarget.21178. eCollection 2017 Oct 6.
2
Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.对于原发性骨髓增生异常综合征患者，骨髓纤维化具有预后价值，可用于当前的治疗方法和新的风险分层系统。
Mod Pathol. 2014 May;27(5):681-9. doi: 10.1038/modpathol.2013.187. Epub 2013 Nov 1.
3
[Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].[血清促红细胞生成素作为骨髓增生异常综合征的预后标志物]
Acta Med Port. 2015 Nov-Dec;28(6):720-5. Epub 2015 Dec 31.
4
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).评估骨髓增生异常综合征（MDS）患者的预后
Cancers (Basel). 2022 Apr 12;14(8):1941. doi: 10.3390/cancers14081941.
5
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.血浆循环微小RNA谱有助于评估细胞遗传学正常的骨髓增生异常综合征患者的预后。
Mod Pathol. 2015 Mar;28(3):373-82. doi: 10.1038/modpathol.2014.108. Epub 2014 Sep 12.
6
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
7
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.自我报告的疲劳对骨髓增生异常综合征患者总生存预后的价值：一项多中心、前瞻性、观察性、队列研究。
Lancet Oncol. 2015 Nov;16(15):1506-1514. doi: 10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21.
8
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.基于疾病状态和骨髓增生异常综合征患者的血液外合并症的风险分层。
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
9
Updates in Risk Stratification in Myelodysplastic Syndromes.骨髓增生异常综合征的风险分层更新。
Cancer J. 2023;29(3):138-142. doi: 10.1097/PPO.0000000000000654.
10
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.治疗相关性与初发性骨髓增生异常综合征患者风险分层工具的临床结局和预后预测价值比较：代表 MDS 临床研究联盟的报告。
Leukemia. 2017 Jun;31(6):1391-1397. doi: 10.1038/leu.2017.33. Epub 2017 Jan 23.

引用本文的文献

1
Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients.CD200 表达和可溶性 CTLA-4 浓度对中高危骨髓增生异常综合征患者的预后价值。
Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2225-2230. doi: 10.31557/APJCP.2020.21.8.2225.
2
Myeloid disorders after autoimmune disease.自身免疫性疾病后的骨髓增生异常。
Best Pract Res Clin Haematol. 2019 Mar;32(1):74-88. doi: 10.1016/j.beha.2019.02.002. Epub 2019 Feb 7.

本文引用的文献

1
Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?治疗相关的骨髓增生异常综合征特异性风险分层：我们是否本末倒置了？
Leukemia. 2017 Nov;31(11):2539-2541. doi: 10.1038/leu.2017.238. Epub 2017 Jul 31.
2
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.治疗相关性与初发性骨髓增生异常综合征患者风险分层工具的临床结局和预后预测价值比较：代表 MDS 临床研究联盟的报告。
Leukemia. 2017 Jun;31(6):1391-1397. doi: 10.1038/leu.2017.33. Epub 2017 Jan 23.
3
Therapy-related myelodysplastic syndromes, or are they?与治疗相关的骨髓增生异常综合征，真的是这样吗？
Blood Rev. 2017 May;31(3):119-128. doi: 10.1016/j.blre.2016.11.002. Epub 2016 Nov 24.
4
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.前列腺癌放疗后骨髓增生异常综合征和急性髓系白血病：一项基于人群的研究。
Prostate. 2017 Apr;77(5):437-445. doi: 10.1002/pros.23281. Epub 2016 Nov 21.
5
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?血液系统恶性肿瘤中分子检测对肿瘤专科医生的意义：进展能否兑现承诺？
Oncologist. 2015 Sep;20(9):1069-76. doi: 10.1634/theoncologist.2015-0067. Epub 2015 Jul 20.
6
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.骨髓增生异常综合征预后和风险分层领域的新进展及未来方向
Blood Rev. 2016 Jan;30(1):1-10. doi: 10.1016/j.blre.2015.06.004. Epub 2015 Jun 19.
7
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.放疗后继发的急性髓系白血病和骨髓增生异常综合征与初发型疾病相似，与其他治疗相关的髓系肿瘤不同。
J Clin Oncol. 2012 Jul 1;30(19):2340-7. doi: 10.1200/JCO.2011.38.7340. Epub 2012 May 14.
8
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.世界卫生组织（WHO）髓系肿瘤和急性白血病分类的2008年修订版：基本原理及重要变化
Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.